Youth Culturally adapted Manual Assisted Problem Solving Training (YCMAP) in Pakistani adolescent with a history of self-harm: protocol for multicentre clinical and cost-effectiveness randomised controlled trial.
child & adolescent psychiatry
mental health
suicide & self-harm
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
13 05 2022
13 05 2022
Historique:
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
20
5
2022
Statut:
epublish
Résumé
Suicide is a global health concern. Sociocultural factors have an impact on self-harm and suicide rates. In Pakistan, both self-harm and suicide are considered as criminal offence's and are condemned on both religious and social grounds. The proposed intervention 'Youth Culturally Adapted Manual Assisted Problem Solving Training (YCMAP)' is based on principles of problem-solving and cognitive-behavioural therapy. YCMAP is a brief, culturally relevant, scalable intervention that can be implemented in routine clinical practice if found to be effective. A multicentre rater blind randomised controlled trial to evaluate the clinical and cost-effectiveness of YCMAP including a sample of 652 participants, aged 12-18 years, presenting to general physicians/clinicians, emergency room after self harm or self referrals. We will test the effectiveness of 8-10 individual sessions of YCMAP delivered over 3 months compared with treatment as usual. Primary outcome measure is repetition of self-harm at 12 months. The seconday outcomes include reduction in suicidal ideation, hopelessness and distress and improvement in health related quality of life. Assessments will be completed at baseline, 3, 6, 9 and 12 months postrandomisation. The nested qualitative component will explore perceptions about management of self-harm and suicide prevention among adolescents and investigate participants' experiences with YCMAP. The study will be guided by the theory of change approach to ensure that the whole trial is centred around needs of the end beneficiaries as key stakeholders in the process. Ethics approval has been obtained from the Ethics Committee of University of Manchester, the National Bioethics Committee in Pakistan. The findings of this study will be disseminated through community workshops, social media, conference presentations and peer-reviewed journals. NCT04131179.
Identifiants
pubmed: 35568489
pii: bmjopen-2021-056301
doi: 10.1136/bmjopen-2021-056301
pmc: PMC9109112
doi:
Banques de données
ClinicalTrials.gov
['NCT04131179']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e056301Subventions
Organisme : Medical Research Council
ID : MR/K005863/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: NH, former Trustee of 'Pakistan Institute of Living and Learning (PILL)', 'Abaseen Foundation (UK)' and 'Lancashire Mind (UK)'. At 'Manchester Global Foundation', he is the Chair of Board of Trustees. He is also a member of the executive committee for the Faculty of Academic Psychiatry, at the Royal College of Psychiatrists. NH is a NIHR Senior Investigator. NC is Associate Director of Global Mental Health and Cultural Psychiatry Research Group. IBC, former Trustee of 'PILL' is Honorary Professor at the University of Manchester. NH, IBC and NC have received support for educational programmes and/or travel support and/or speaker fees from pharmaceutical companies. CW is the author of a book aimed at suicide prevention, and has written a range of books and online CBT-based course resources that are available as both, free access and on a commercial basis. NH, NC, IBC and TK’s time is partially funded by the Global Challenges Research Fund 'South Asia Harm Reduction Movement-SAHAR M' (MR/P028144/1).
Références
Br J Psychiatry. 2014 Jun;204(6):462-70
pubmed: 24676964
Qual Life Res. 2010 Aug;19(6):887-97
pubmed: 20401552
Psychol Med. 2018 Apr;48(5):714-727
pubmed: 28830574
Aust N Z J Public Health. 2001 Dec;25(6):494-7
pubmed: 11824981
J Pak Med Assoc. 2003 Apr;53(4):142-7
pubmed: 12776898
Lancet. 2012 Jun 23;379(9834):2373-82
pubmed: 22726518
Neuropsychiatr Dis Treat. 2018 Jan 04;14:165-178
pubmed: 29379289
PLoS One. 2010 Feb 23;5(2):e9373
pubmed: 20186326
Lancet Reg Health Eur. 2022 Apr 01;16:100341
pubmed: 35392452
Psychol Assess. 2006 Sep;18(3):303-12
pubmed: 16953733
Acta Psychiatr Scand. 1992 Feb;85(2):97-104
pubmed: 1543046
BMC Psychiatry. 2018 Feb 12;18(1):44
pubmed: 29433468
Psychiatry Res. 2019 Sep;279:201-206
pubmed: 30851986
Br Med Bull. 2015 Jun;114(1):127-34
pubmed: 25958380
Front Psychiatry. 2021 May 20;12:607549
pubmed: 34093256
Stat Methods Med Res. 2018 Dec;27(12):3612-3627
pubmed: 28589752
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
BMC Psychiatry. 2014 Dec 24;14:358
pubmed: 25539951
Asian J Psychiatr. 2015 Feb;13:3-12
pubmed: 25499463
Psychol Med. 2016 Jan;46(2):225-36
pubmed: 26370729
Eval Program Plann. 1982;5(3):233-7
pubmed: 10259963
Crisis. 2008;29(4):213-5
pubmed: 19069614
Cochrane Database Syst Rev. 2015 Dec 21;(12):CD012013
pubmed: 26688129